Quantum BioPharma

QNTM

The current Quantum BioPharma (QNTM) market capitalization is approximately CA$40.08M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Quantum BioPharma's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:42 PM Eastern Time

In the most recently reported quarter, Quantum BioPharma (QNTM) generated CA$0.00 in revenue. For the next quarter, analyst consensus currently expects revenue of approximately CA$0.00. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 2:23 AM Eastern Time

In the most recently reported fiscal year, Quantum BioPharma (QNTM) generated net income of CA$-39.62M, compared with CA$-52.01M in the prior fiscal year, representing a +23.83% year over year change. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 2:23 AM Eastern Time

According to its latest quarterly filing, Quantum BioPharma (QNTM) reported EBITDA of CA$-6.31M, representing a -15.10% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: January 1, 2026 at 2:23 AM Eastern Time

As of the most recent reporting period, the company's debt-to-equity ratio stands at 0.34x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: January 1, 2026 at 2:23 AM Eastern Time

In the most recently reported quarter, Quantum BioPharma (QNTM) revenue was CA$0.00, compared with analyst consensus expectations of CA$1.24M, representing a -100.00% revenue surprise versus expectations. Earnings per share (EPS) for the quarter were CA$-1.95. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 2:23 AM Eastern Time

Quantum BioPharma (QNTM) does not currently pay a dividend. Over the last twelve months (LTM), the company paid CA$0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 2:23 AM Eastern Time

Based on the latest available analyst coverage, Quantum BioPharma (QNTM) currently carries a Buy consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated:

Like other publicly traded stocks, Quantum BioPharma (QNTM) shares are bought and sold on stock exchanges such as CNSX and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Quantum BioPharma (QNTM) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add QNTM to your watchlist.

Quantum BioPharma trades under the ticker symbol QNTM on the CNSX stock exchange. The ticker QNTM is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Quantum BioPharma (QNTM) employs approximately 17 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: December 31, 2025 at 11:42 PM Eastern Time

Quantum BioPharma (QNTM) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Quantum BioPharma (QNTM) stock peers based on overlapping products, services, and competitive dynamics:Clearmind Medicine (CMND)NervGen Pharma (NGEN)BioNxt Solutions (BNXT)PharmaTher Holdings (PHRM)MindBio Therapeutics (MBIO)Avicanna (AVCN)Revive Therapeutics (RVV)ZYUS Life Sciences (ZYUS) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Quantum BioPharma.